A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

Published: 08-03-2021| Version 1 | DOI: 10.17632/ctdyb5zvs5.1
Contributor:
Ashish Bansal

Description

Author video for the article: Paller AS, Siegfried EC, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35(2):464-475.

Files